

Clinical trials of immune checkpoint inhibition for multiple myeloma in all type of patients

TrialResults-center www.trialresultscenter.org

1 PD1 inhibitors

Trial	Treatments	Patients	Trials design and methods
Nivolumab, Elotuzumab, Pomalidomide, dexaM vs			
CheckMate 602 <i>ongoing</i> [NCT02726581] n=NA follow-up:	nivolumab, pomalidomide and dexamethasone versus pomalidomide and dexamethasone	-	open-design
pembrolizumab, lenalidomide, dexamethasone vs lenalidomide, dexamethasone			
KEYNOTE-185 , 2018 [NCT02579863] n=151/150 follow-up:	-	newly diagnosed and treatment nave Multiple Myeloma who are ineligible for autologous stem cell transplant	Parallel groups open-design
pembrolizumab + pomadoline + dexamethasone vs pomadoline + dexamethasone			
KEYNOTE-183 , 2018 [NCT02576977] n=125/124 follow-up: 7.8 mo / 8.6 mo (median)	pembrolizumab, Pomalidomide and low-dose Dexamethasone versus Pomalidomide and low-dose Dexamethasone	refractory or relapsed and refractory Multiple Myeloma (rrMM)	Parallel groups open-design

References

CheckMate 602, :

KEYNOTE-185, 2018:

KEYNOTE-183, 2018:

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.